Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360447" target="_blank" >RIV/00216208:11110/17:10360447 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61383082:_____/17:00000287 RIV/00064165:_____/17:10360447

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.pan.2016.12.004" target="_blank" >http://dx.doi.org/10.1016/j.pan.2016.12.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pan.2016.12.004" target="_blank" >10.1016/j.pan.2016.12.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

Popis výsledku v původním jazyce

Background: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. Methods: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. Results: Significantly lower plasma concentrations of GIP were found in PDAC patients with new -onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1 -104.7) and 28.8 (7.4-112.2) ng/L, p &lt; 0.001); the same relationship was observed for PP (38.9 (10.2 -147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p &lt; 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new -onset diabetes/prediabetes and weight loss &gt; 2 kg (p &lt; 0.001). Conclusions: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.

Název v anglickém jazyce

Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

Popis výsledku anglicky

Background: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. Methods: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. Results: Significantly lower plasma concentrations of GIP were found in PDAC patients with new -onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1 -104.7) and 28.8 (7.4-112.2) ng/L, p &lt; 0.001); the same relationship was observed for PP (38.9 (10.2 -147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p &lt; 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new -onset diabetes/prediabetes and weight loss &gt; 2 kg (p &lt; 0.001). Conclusions: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

<a href="/cs/project/NT14254" target="_blank" >NT14254: Časná diagnostika adenokarcinomu pankreatu: povrchové proteázy a specifické biomarkery</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pancreatology

ISSN

1424-3903

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

6

Strana od-do

89-94

Kód UT WoS článku

000393634200018

EID výsledku v databázi Scopus

2-s2.0-85008194787